| Document |
Document Title |
|
WO/2023/033174A1 |
This phytin has improved solubility in water. The present application provides a phytin that contains calcium and/or magnesium at a specific mole ratio with respect to phytic acid.
|
|
WO/2023/033681A1 |
Disclosed are substituted 2-(5-aryl-4H-1,2,4-triazol-3-yl)ethanamines of general formula 1 and their pharmaceutically acceptable salts which are modulators of trace amine-associated receptor 1 (TAAR1). The method for producing the compou...
|
|
WO/2023/032726A1 |
This cyclic peptide or salt thereof comprises either the amino acid sequence indicated in SEQ ID NO: 1, or an amino acid sequence obtained by deleting or substituting the amino acid of the N-terminus and/or the amino acid of the C-termin...
|
|
WO/2023/034265A1 |
Methods of treating pharyngeal airway collapse (e.g., sleep apnea) by administering a norepinephrine reuptake inhibitor (NRI) in combination with mandibular advancement device (MAD) therapy are described herein. The treatment may further...
|
|
WO/2023/032987A1 |
Provided are: a 6-aminopyrazolopyrimidine compound having an inhibitory activity on NLRP3 inflammasomes or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing the same; and a pharmaceutical use thereof. A ...
|
|
WO/2023/033534A1 |
The KAI1 protein or a fragment thereof according to the present invention inhibited hepatic fibrosis in mice in which acute hepatic fibrosis was induced by CCl4. The KAI1 protein suppressed hepatic fibrosis by inhibiting fibrosis of hepa...
|
|
WO/2023/033098A1 |
The present invention provides a compound that exhibits an inhibitory activity against coronavirus 3CL protease or a pharmaceutically acceptable salt thereof and a pharmaceutical composition containing the same. A compound represented by...
|
|
WO/2023/033680A1 |
7-Substituted 2,3,4,5-tetrahydrobenzo[f][1,4]oxazepines of general formula 1 and their pharmaceutically acceptable salts which are modulators of trace amine-associated receptor 1 (TAAR1) are disclosed. The method for producing the compou...
|
|
WO/2023/032788A1 |
Provided are a protective agent, a surfactant composition, a composition for blood sugar level control, an autophagy inducing agent, a stain for mycobacteria, or a protein extraction agent characterized by containing a compound represent...
|
|
WO/2023/028513A1 |
Provided herein are pharmaceutical compositions (e.g., formulations) that can provide for the long-term stability of AAV vectors. Also provided herein are methods of making and using the pharmaceutical compositions. The pharmaceutical co...
|
|
WO/2023/024552A1 |
Disclosed in the present invention are a recombinant type-I humanized collagen polypeptide, and a preparation method therefor and the use thereof. The recombinant type-I humanized collagen polypeptide provided by the present invention co...
|
|
WO/2023/026957A1 |
Provided is an agent for the prevention and/or treatment of Porphyromonas gingivalis infection. An agent for the prevention and/or treatment of Porphyromonas gingivalis infection that contains killed Enterococcus faecalis. An agent for t...
|
|
WO/2023/026794A1 |
[Problem] To provide: a composition that suppresses mature-hepatocyte transdifferentiation or a composition that is capable of treating cholangiocarcinoma; and a screening method for substances for suppressing mature-hepatocyte transdiff...
|
|
WO/2023/027082A1 |
The present invention addresses the problem of providing a hybrid liposome exosome or the like capable of delivering an active ingredient to a target cell at a higher concentration. This peptide-bound hybrid liposome exosome, which inc...
|
|
WO/2023/027132A1 |
The present invention provides: a bone metabolic cell modulator including at least one polypeptide selected from the group consisting of Chromosome 4 Open Reading Frame 48 (C4orf48), C4orf48 variants having at least one among the ability...
|
|
WO/2023/001234A9 |
A modified small interfering RNA (siRNA) molecule comprising phosphorothioate (PS) intemucleotide linkages in the antisense strand for reducing off-target effects and methods and uses thereof. The siRNAs targeting Hypoxia Inducible Facto...
|
|
WO/2023/023994A1 |
A drug for improving the chemotaxis of anti-inflammatory macrophages and the use thereof in the preparation of a drug for improving the chemotaxis of anti-inflammatory macrophages. The active ingredient of the drug is glucosamine. In vit...
|
|
WO/2023/027177A1 |
The purpose of the present invention is to provide a bispecific antibody and a fragment of said bispecific antibody that have an agonist activity against GM-CSF receptors. The present invention relates to a bispecific antibody, or a frag...
|
|
WO/2023/027098A1 |
The present invention provides: an anti-HBV agent that contains a substance that suppresses the expression or inhibits the activity of hypoxia-inducible factor prolyl hydroxylase (HIF-PH); a pharmaceutical composition for treating or pre...
|
|
WO/2023/028586A1 |
Provided herein are methods of using taxifolin for treating or preventing systemic lupus erythematosus a thromboinflammatory disease, or cystic fibrosis in a subject.
|
|
WO/2023/027088A1 |
This composition for improving the drug sensitivity of an antibacterial drug to methicillin-resistant Staphylococcus aureus (MRSA) comprises at least one bacteriophage selected from the group consisting of the bacteriophage identified by...
|
|
WO/2023/027065A1 |
The present invention provides a novel method for producing a 2'-modified guanosine compound represented by the formula. In the formula, R1 and R2 may be the same or different, and each represents a hydrogen atom, an optionally substitut...
|
|
WO/2023/027198A1 |
The present invention provides a preparation for oral administration containing a triazine derivative that exhibits a viral proliferation inhibiting action.
|
|
WO/2023/027032A1 |
Provided are a self degradation-type CDK9 inhibitor prodrug and a liposome encapsulating same. The present invention pertains to a compound represented by formula (1), or a pharmaceutically acceptable salt thereof [in the formula, R1 rep...
|
|
WO/2023/027164A1 |
The present invention addresses the problem of providing an ROS production promoter. The present invention provides an ROS production promoter that contains an agent that recognizes a transferrin receptor.
|
|
WO/2023/022198A1 |
A prophylactic or therapeutic agent for a novel coronavirus infection (COVID-19)-related disease, said agent comprising a cephem compound and/or a quinolone antimicrobial agent as an active ingredient.
|
|
WO/2023/020488A1 |
A use of and method for telaprevir in the preparation of a drug and a cytoprotective drug for treating ischemia/reperfusion injury. Telaprevir is used for the preparation of a drug for treating ischemia/reperfusion injury, in particular ...
|
|
WO/2023/020762A1 |
The presented invention relates to Tafamidis nicotinamide adduct, solid form thereof, crystalline form thereof, processes for preparation thereof and a composition comprising it.
|
|
WO/2022/047209A9 |
This invention relates to methods for selecting a treatment and optionally treating subjects with muscle-invasive bladder cancer based on tumor expression levels of chemokines, cytotoxic genes, and/or dendritic cell genes.
|
|
WO/2023/022235A1 |
The present invention discloses administering a trinapant-type-drug-containing pharmaceutical composition in combination with a pharmaceutical composition that contains immune cells modified to express chimeric antigen receptors or recom...
|
|
WO/2023/022473A1 |
The present invention relates to a pharmaceutical composition comprising pineal gland hormone-treated mesenchymal stem cell-derived extracellular vesicles as an active ingredient. The extracellular vesicles extracted from pineal gland ho...
|
|
WO/2023/019389A1 |
Provides are sealed bacterial ghosts, methods and compositions for producing sealed bacterial ghosts, and methods and compositions for using sealed bacterial ghosts for delivering drugs, treating or preventing diseases and other medical ...
|
|
WO/2023/019499A1 |
Disclosed in the present invention are an elastase inhibitor and the use thereof in disease treatment, which belongs to the field of medicines. Specifically, disclosed are a compound of formula (I), a pharmaceutical composition containin...
|
|
WO/2023/022522A1 |
The present disclosure relates to a pharmaceutical preparation for treating or preventing steatohepatitis, steatosis and/or fibrosis, containing two active ingredients. The present disclosure relates to a complex preparation. The present...
|
|
WO/2023/017836A1 |
THE present invention includes a pharmaceutical composition for the treatment or prevention of cancer in HLA-A*11:01-, HLA-A*02:01-, HLA-A*02:06-, HLA-A*02:07-, HLA-A*26:01-, HLA-A*26:03-, HLA-A*01:01-, HLA-B*15:01-, HLA-B*35:01-, HLA-C*...
|
|
WO/2023/018801A1 |
The present invention provides methods treating disease and disorders of the hematological system.
|
|
WO/2023/016852A1 |
The present invention relates to a composition for oral subministration, as food supplementation or medical purposes and, in particular, to a composition comprising amino acids, which is effective as a vasodilator and/or in a method for ...
|
|
WO/2023/018795A1 |
The present disclosure relates to methods, uses, pharmaceutical compositions and kits comprising an NEP inhibitor or a pharmaceutically acceptable salt thereof, alone or in combination with one or more additional therapeutic agents, for ...
|
|
WO/2023/019189A1 |
This invention relates to methods and compositions for gene therapy. In particular, the invention relates to compositions for enhancing delivery of therapeutic products to bystander cells that have not received the expression vector enco...
|
|
WO/2023/013613A1 |
The present invention addressing the problem of providing: a method for forming a three-dimensional structure dynamically by utilizing non-complementary base pairs in an oligonucleotide therapeutic; a modification mode for a nucleic acid...
|
|
WO/2023/011638A1 |
The present invention relates to a fusion protein and a use method thereof. The fusion protein comprises a first protein and a second protein; the first protein is Cas, such as Cas9, Cas12a, Cas12b, Cas12e and TALEN or ZFN; the second pr...
|
|
WO/2023/013756A1 |
The present invention addresses the problem of providing a low molecular weight compound that has an action of increasing the NAD+ amount in animal cells and that has a low cellular toxicity against animal cells. The present invention ...
|
|
WO/2023/013785A1 |
Provided is a nucleic acid structure that enhances an antigen-specific immune response. The nucleic acid structure includes a polynucleotide that codes for any SNARE protein selected from the group consisting of VAMP7, GOSR2, STX10, STX1...
|
|
WO/2023/013786A1 |
Provided is a nucleic acid structure that enhances an antigen-specific immune response. The nucleic acid structure includes a polynucleotide that codes for a SNARE protein, a polynucleotide that codes for a proprotein convertase recognit...
|
|
WO/2023/014062A1 |
Disclosed in the present invention are: a pharmaceutical composition for preventing or treating fibrotic diseases, comprising hyaluronan and proteoglycan link protein 1 (HAPLN1) or a gene encoding same as an active ingredient; and a meth...
|
|
WO/2023/013763A1 |
The present invention provides a novel and effective cancer immunotherapeutic agent exhibiting a therapeutic effect against refractory cancers, particularly against cancers for which immune checkpoint inhibitors used as a monotherapy or ...
|
|
WO/2023/011635A1 |
The use of montelukast or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of an immunodeficiency disorder and also for the treatment of a disorder characterized by inflammation in a patien...
|
|
WO/2023/013719A1 |
There has been demand to identify miRNA that could be made to be involved in treatment and/or prevention in common across various cancer types from a variety of miRNA relating to cancer, and to provide a novel pharmaceutical composition ...
|
|
WO/2023/014003A1 |
The present invention relates to a composition for treating hypertrophic scars and keloids, comprising a benzhydryl thioacetamide compound as an active ingredient. The benzhydryl thioacetamide compound inhibits cell proliferation and an ...
|
|
WO/2023/013409A1 |
The present disclosure relates to providing a cytoprotectant and a thermal oxidation inhibitor that protect the skin from infrared damage and heat damage. More particularly, there are provided a cytoprotectant and a thermal oxidation inh...
|
